CSL Seqirus and Arcturus Ink $4.3 Billion mRNA Vaccine DealTherapeuticsThe two companies will work to advance vaccines against COVID-19, influenza, pandemic preparedness and three other common respiratory infectious diseases. Read more November 2, 2022/by BioSpace https://www.pharmalive.com/wp-content/uploads/2022/11/Patient-getting-vaccine.jpeg 350 625 BioSpace https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png BioSpace2022-11-02 18:00:182022-11-03 10:12:45CSL Seqirus and Arcturus Ink $4.3 Billion mRNA Vaccine Deal